Table 2. Effect of VEGF-D on benefit of bevacizumab on response rate, progression-free survival, and overall survival.
| VEGF-D expression | Treatment | Response rate (%) | Median progression-free survival (months) | Median overall survival (months) |
|---|---|---|---|---|
| 0, 1 | C | 36 | 5.8 | 18.9 |
| 0, 1 | CB+CBM | 33 | 16.8 | NR |
| 2 | C | 31 | 6.0 | 20.6 |
| 2 | CB+CBM | 34 | 8.8 | 21.6 |
| 3 | C | 52 | 7.0 | 24.6 |
| 3 | CB+CBM | 52 | 9.0 | 19.4 |
Abbreviations: C=capecitabine; CB=capecitabine and bevacizumab; CBM=capecitabine, bevacizumab, and mitomycin; NR=not recorded; VEGF=vascular endothelial growth factor.